<DOC>
	<DOCNO>NCT00549939</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy Alfuzosin comparison Placebo detrusor Leak Point Pressure ( LPP ) child adolescents 2-16 year age elevate detrusor LPP neuropathic etiology detrusor LPP ≥ 40 cm H2O . Secondary objective : - To investigate safety tolerability two dos Alfuzosin comparison Placebo child adolescent , - To evaluate effect two dos Alfuzosin comparison Placebo : - Detrusor compliance , - Urinary tract infection , - To investigate pharmacokinetics Alfuzosin ( population kinetics ) , - To evaluate 12-month long-term safety Alfuzosin 0.1 mg/kg/day 0.2 mg/kg/day . The study consist 2 period : - 12-week double blind treatment period patient receive either Alfuzosin 0.1 mg/kg/day Alfuzosin 0.2 mg/kg/day placebo , - 40-week open label extension treatment period patient receive either Alfuzosin 0.1 mg/kg/day Alfuzosin 0.2 mg/kg/day .</brief_summary>
	<brief_title>Alfuzosin Treatment Children Adolescents With Neurogenic Urinary Bladder Dysfunction</brief_title>
	<detailed_description>Patients meet study entry criterion randomize ( 2:1:2:1 ) one 4 dosage group ( Alfuzosin 0.1 mg/kg/day , match placebo 0.1 mg/kg/day , Alfuzosin 0.2 mg/mg/kg , match placebo 0.2 mg/kg/day ) . Patients receive treatment use either solution tablet formulation depend age follow : - Solution child 2-7 year age , child adolescents 8-16 year age unable swallow tablet prefer take solution body weight &lt; 30kg . The daily dose devided 3 dos give breakfast , lunch dinner . - Tablet child adolescents 8-16 year age able swallow tablet body weight ≥ 30kg . The daily dose devided 2 dos give breakfast dinner . Patients complete 12-week double-blind phase offer continue 40-week open-label extension study . - Patients receive Alfuzosin continue dose regimen . - Patients receive Placebo switch Alfuzosin dose correspond randomization dose group . All patient one-week follow-up period last dose intake .</detailed_description>
	<mesh_term>Urinary Bladder , Neurogenic</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Patient elevate detrusor Leak Point Pressure ( LPP ) neuropathic etiology Detrusor LPP ≥ 40 cm H2O &lt; 100 cm H2O . Urological surgery last 4 month prior study , Patients urethral dilatation last 3 month prior baseline urodynamic assessment , αblocker therapy last 4 week prior baseline urodynamic assessment , Detrusor injection botulinum toxin last 6 month , Urological diseases/conditions functional bladder obstruction neuropathic etiology lead upper urinary tract dilatation ( e.g. , bladder anomaly , ureterocele ) , History intolerance αblocker therapy , Orthostatic hypotension , History risk factor Torsade de pointes ( e.g. , family history Long QT Syndrome ) . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>child</keyword>
	<keyword>bladder</keyword>
	<keyword>neuropathic</keyword>
	<keyword>alpha blocker</keyword>
</DOC>